Daily Cardiology Research Analysis
Analyzed 44 papers and selected 3 impactful papers.
Summary
A multicenter randomized trial showed that a generative AI-enabled low-dose digital subtraction angiography protocol markedly reduced intra-operative radiation without compromising workflow. Multi-omics profiling defined a metabolome-informed obesity metric that outperforms BMI in stratifying cardiometabolic risk and links adiposity to the microbiome. An individual patient data meta-analysis supports safe prehospital low-risk stratification of suspected NSTE-ACS using HEART-derived scores with point-of-care troponin.
Research Themes
- AI-driven procedural optimization and radiation safety
- Multi-omics and microbiome for cardiometabolic risk stratification
- Prehospital triage for suspected NSTE-ACS using POC troponin and clinical risk scores
Selected Articles
1. Generative AI-based low-dose digital subtraction angiography for intra-operative radiation dose reduction: a randomized controlled trial.
In a multicenter randomized controlled trial, a generative AI-enabled low-dose DSA protocol reduced intra-operative radiation substantially versus standard protocols, with mean air kerma lowered by 306 mGy. Blinding of patients, surgeons, and investigators strengthens the validity, while secondary outcomes assessed efficiency and complications.
Impact: This is among the first prospective randomized validations of a generative AI imaging protocol demonstrating clinically meaningful radiation reduction. It can reshape procedural imaging safety across interventional fields, including cardiac catheterization.
Clinical Implications: Interventional teams can adopt AI-enabled low-dose DSA workflows to reduce radiation to patients and staff without compromising procedural efficiency. This supports broader radiation stewardship in catheterization labs and may inform dose benchmarks and device procurement.
Key Findings
- Randomized, multicenter validation in 1,068 patients across 70 centers comparing GenDSA-V2 vs standard protocols.
- Air kerma reduced to 151.3 ± 125.1 mGy vs 457.4 ± 407.4 mGy (mean difference −306.1 mGy; 95% CI −342.3 to −269.9; P < 0.001).
- Dose-area product in the AI group averaged 4009.7 ± 2767.9 μGy·m², with secondary endpoints assessing efficiency, procedure time, and complications.
Methodological Strengths
- Prospective multicenter randomized controlled design with blinding of patients, surgeons, and investigators
- Large-scale algorithm development dataset (46,829 patients; >5 million images) and pragmatic clinical validation
Limitations
- Technicians were not blinded, which may introduce procedural behavior bias
- The study encompassed diverse indications (neuro, thoracic, hepatic) rather than exclusively cardiology, potentially affecting generalizability to cath labs
- Secondary outcomes (efficiency, time, complications) details not fully reported in the abstract
Future Directions: Head-to-head comparisons across different vendors and cath lab settings, assessment of long-term operator exposure, and evaluation of clinical outcomes and cost-effectiveness will support broader adoption.
Digital subtraction angiography (DSA) devices guide procedures across numerous diseases, performed on more than 100,000 patients daily worldwide. However, these procedures expose patients and healthcare providers to radiation, increasing the risk of health issues. Despite many low-dose DSA imaging methods proposed, none have been prospectively clinically validated. In this study, 46,829 patients (over 5 million DSA images) from 70 centers were used to iterate our previously developed generative artificial intelligence system (named GenDSA-V2). A total of 1,068 patients (533 in intervention arm and 535 in control arm), with suspected cerebral aneurysms (n = 435), lung cancer (n = 417) or advanced liver cancer (n = 216), meeting surgical criteria, were enrolled to validate the GenDSA-V2. The primary outcome was radiation dose, while secondary outcomes included efficiency, operation time and intraoperative complications. Group assignments were blinded to patients, surgeons and investigators, while technicians were aware but not involved in data collection or analysis. The GenDSA-V2 group showed substantially reduced radiation exposure, with an air kerma (AK) of 151.3 ± 125.1 mGy compared to 457.4 ± 407.4 mGy in the standard clinical protocols (SCP) group (mean difference = -306.1 mGy, 95% confidence interval (CI) = -342.3 to -269.9, P < 0.001 for superiority) and a dose-area product (DAP) of 4009.7 ± 2767.9 μGy m
2. Multi-omic definition of metabolic obesity through adipose tissue-microbiome interactions.
A metabolomics-informed obesity metric (metBMI) derived from deep multi-omics better captures adipose dysfunction and predicts adverse cardiometabolic phenotypes than BMI, with external validation. The signature is tightly linked to microbiome diversity and function, and a 66-metabolite panel preserves substantial predictive power.
Impact: Defines a practical, mechanistically anchored, multi-omic metric that outperforms BMI for risk stratification and aligns with microbiome biology, paving the way for precision cardiometabolic care.
Clinical Implications: metBMI can help identify high-risk adiposity phenotypes (e.g., fatty liver, insulin resistance) and may inform targeted lifestyle, pharmacologic, or microbiome-modulating interventions, as well as trial enrichment strategies.
Key Findings
- metBMI explained 52% of BMI variance in an external cohort (n=466) and more accurately reflected adiposity than other omics models.
- High metBMI associated with 2–5-fold higher odds of fatty liver, diabetes, severe visceral adiposity, insulin resistance, hyperinsulinemia, and inflammation.
- In bariatric surgery patients (n=75), higher metBMI predicted 30% less weight loss.
- A 66-metabolite panel retained 38.6% explanatory power; 90% of metabolites covaried with the microbiome; mediation showed a bidirectional host-microbiome axis.
Methodological Strengths
- Large discovery cohort with external validation and bariatric surgery subcohort
- Integrated multi-omics with microbiome linkage and mediation analysis
Limitations
- Observational design limits causal inference
- Generalizability across ancestries and clinical settings requires further validation
- Clinical utility thresholds and implementation pathways remain to be established
Future Directions: Prospective interventional studies testing metBMI-guided prevention/treatment, standardization of the 66-metabolite panel, and evaluation of microbiome-targeted therapies based on metBMI.
Obesity's metabolic heterogeneity is not fully captured by body mass index (BMI). Here we show that deep multi-omics phenotyping of 1,408 individuals defines a metabolome-informed obesity metric (metBMI) that captures adipose tissue-related dysfunction across organ systems. In an external cohort (n = 466), metBMI explained 52% of BMI variance and more accurately reflected adiposity than other omics models. Individuals with higher-than-expected metBMI had 2-5-fold higher odds of fatty liver disease, diabetes, severe visceral fat accumulation and attenuation, insulin resistance, hyperinsulinemia and inflammation and, in bariatric surgery (n = 75), achieved 30% less weight loss. This obesogenic signature aligned with reduced microbiome richness, altered ecology and functional potential. A 66-metabolite panel retained 38.6% explanatory power, with 90% covarying with the microbiome. Mediation analysis revealed a bidirectional, metabolite-centered host-microbiome axis, mediated by lipids, amino acids and diet-derived metabolites. These findings define an adipose-linked, microbiome-connected metabolic signature that outperforms BMI in stratifying cardiometabolic risk and guiding precision interventions.
3. Prehospital risk stratification in suspected non-ST-segment elevation acute coronary syndrome with point-of-care troponin: an individual patient data meta-analysis.
Across 5,239 EMS patients in six prospective studies, HEART-derived clinical risk scores with point-of-care troponin identified very-low-risk NSTE-ACS patients with high 30-day NPV (97–99.8%) and sensitivity (>91%). Lowering cut-offs increased safety further but reduced the proportion classified as low risk.
Impact: Provides IPD-level evidence supporting safe prehospital low-risk discharge pathways for suspected NSTE-ACS, a key operational gap in EMS care.
Clinical Implications: EMS can implement HEART+POC troponin protocols to triage low-risk chest pain patients for deferred ED evaluation or alternative pathways, provided reliable follow-up is ensured.
Key Findings
- IPD meta-analysis of 6 prospective EMS studies totaling 5,239 patients using HEART-derived scores with POC troponin.
- 30-day all-cause mortality: sensitivity 93.2% (83.5–98.1), NPV 99.8% (99.5–99.9).
- 30-day mortality and/or AMI: sensitivity 91.8% (83.0–96.2), NPV 97.3% (89.9–99.3).
- 30-day MACE: sensitivity 92.8% (88.7–95.5), NPV 97.2% (92.1–99.0).
- Lower CRS cut-offs improve sensitivity/NPV but reduce the proportion labeled low risk.
Methodological Strengths
- Individual patient data meta-analysis of prospective EMS studies
- Consistent endpoints at 30 days with sensitivity and NPV estimates across clinically relevant composites
Limitations
- Heterogeneity in EMS infrastructure, POC assays, and follow-up pathways limits generalizability
- Implementation requires reliable outpatient follow-up, which may not be available in all systems
Future Directions: Pragmatic cluster-RCTs of prehospital HEART+POC troponin discharge pathways, integration of high-sensitivity assays, and cost-effectiveness analyses across diverse EMS systems.
BACKGROUND: Emergency Medical Services (EMS) patients with chest pain are often suspected of having non-ST-elevation acute coronary syndrome (NSTE-ACS). Current risk stratification protocols for NSTE-ACS have limitations, leading to a lack of a well-organised prehospital diagnostic pathway. Recent studies have demonstrated that using clinical risk scores (CRS) including point-of-care (POC)-troponin in the EMS can improve prehospital diagnostic pathways for suspected NSTE-ACS. The primary aim of this systematic review and individual patient data meta-analysis was to assess safety of low-risk stratification for suspected NSTE-ACS patients in the prehospital setting. METHODS: Prospective studies using CRS or POC-troponin for risk stratification in suspected NSTE-ACS patients within the EMS setting were included. Safety was assessed using sensitivity and negative predictive value (NPV) for patients identified as low risk, based on CRS or POC-troponin measurement, for three different endpoints within 30 days: (1) all-cause mortality, (2) composite of mortality and/or acute myocardial infarction (AMI), (3) major adverse cardiac events (MACE). RESULTS: Of 1526 articles screened, 6 were included, comprising 5.239 patients, and all utilised CRS derived from the History, ECG, Age, Risk-factor and Troponin (HEART) score. The summary of low-risk CRS diagnostic performance predicted all-cause mortality with a sensitivity of 93.2% (83.5-98.1) and NPV of 99.8% (99.5-99.9); mortality and/or AMI with a sensitivity of 91.8% (83.0-96.2) and an NPV of 97.3% (89.9-99.3); and MACE with a sensitivity of 92.8% (88.7-95.5) and an NPV of 97.2% (92.1-99.0). Lowering the CRS cut-off value for identifying low-risk patients increased sensitivity and NPV but decreased the proportion of patients classified as low risk. CONCLUSION: In well-trained EMS systems, where prompt and accurate follow-up of low-risk patients is possible, HEART-derived CRS effectively identify patients with a very low risk of 30-day mortality and MACE. However, implementation in other healthcare systems requires additional validation, given the variations in healthcare structure, risk stratification processes and follow-up capabilities.